Le Lézard
Classified in: Health

CIRCULOGENE announces plasma PD-L1 data presented at the ASTRO / ASCO Multidisciplinary Thoracic Cancers Symposium

BIRMINGHAM, Ala. and PENSACOLA, Fla., Dec. 2, 2021 /PRNewswire-PRWeb/ -- CIRCULOGENE, an innovative medical technology company transforming precision medicine through the rapid delivery of actionable results, today announced plasma PD-L1 outcomes data presented at the American Society for Radiation Oncology (ASTRO) Multidisciplinary Thoracic Cancers Symposium being held December 2-4 at the Fairmont Scottsdale Princess in Scottsdale, Arizona.

Conclusions of Data Presented:
? Plasma cell free PD-L1 RNA (cfRNA) expression was predictive of survival benefit of immunotherapy treatment over chemotherapy in a real-world population of advanced non-small cell lung cancer (NSCLC) patients.
? The 3-year landmark outcome study of 30% parallels tissue PD-L1 predictive clinical trial outcomes.

"This data demonstrates that liquid PD-L1 RNA expression is as clinically beneficial as tissue PD-L1," Dr. Paul Walker, Chief Medical Officer of CIRCULOGENE said. "Plasma PD-L1 has significant clinical utility guiding immunotherapy treatment."

"CIRCULOGENE offers the only tumor molecular test including liquid/plasma PD-L1 that has been demonstrated to be predictive of immunotherapy survival benefit," said Mike Mullen, President and CEO of CIRCULOGENE. "The presence of PD-L1 is important to oncologists for making effective patient treatment decisions such as immunotherapy versus chemotherapy. Getting the right treatment to the right patient leads to better outcomes."

Dr. Walker's pre-recorded review of the study and clinical outcome can be viewed on the CIRCULOGENE YouTube Channel.

CIRCULOGENE provides comprehensive biomarker testing for a broad range of cancers, allowing physicians to match patient results with specific therapies in just one week. The company has developed proprietary enrichment technology to minimize genetic data loss, so their sequencing and qPCR methods can provide a full genomic load analysis which helps clinicians select targeted therapies, monitor efficacy, and assess recurrence for cancer patients. Applying their proprietary liquid biopsy innovation for cfDNA and cfRNA, including PD-L1 and MSI detection, CIRCULOGENE can detect circulating germline and somatic mutations and RNA fusions.

CIRCULOGENE is a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) certified laboratory and a Verified Vendor for the federal System for Award Management. For more information, visit our website at circulogene.com, connect with us on LinkedIn, Facebook, and Twitter, email info@circulogene.com, or call us at 855-614-7083. Clinicians interested in ordering tests may also visit our contact page at circulogene.com/contact.

Media Contact

Scott Rezek, CIRCULOGENE, +1 (205) 278-1607, srezek@circulogene.com



These press releases may also interest you

at 05:31
Ascletis Pharma Inc. (HKEX code: 1672) today announces the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). ASC40 is an oral, selective...

at 03:00
In 1825, John Quincy Adams signed a treaty that required Native Americans in Georgia to relinquish their claim on their land. It was a decision he regretted almost immediately, later declaring such policies to be "among the heinous sins of this...

22 jan 2022
POWERHANDZ is a global athletic training and rehabilitation product tech company transforming the way athletes and patients improve human performance through the combined use of smart sports products, technology and services for any stage of life....

22 jan 2022
Summary Brand(s): Searay Product: Sauerkraut Fish (Szechuan Style) Spicy Companies: Searay Foods Inc. Issue: Food ? Allergen ? Milk Category: Fish and seafood (Frozen) What to do: If you have an allergy to milk, do not consume the recalled product...

22 jan 2022
Summary Brand(s): Shirakiku Product: Baked Red Bean Cake Companies: Wismettac Asian Foods, Inc. Issue: Food ? Allergen ? Milk Category: Grain products What to do: If you have an allergy to milk, do not consume the recalled product Audience: General...

22 jan 2022
Natera, Inc. , a leader in personalized genetic testing and diagnostics, today announced new data recently presented on the clinical utility of Signatera, its personalized and tumor-informed molecular residual disease (MRD) test, at the American...

News published on 2 december 2021 at 13:00 and distributed by: